Compare HLLY & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HLLY | VNDA |
|---|---|---|
| Founded | 1903 | 2002 |
| Country | United States | United States |
| Employees | 1483 | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 378.7M | 400.8M |
| IPO Year | N/A | 2005 |
| Metric | HLLY | VNDA |
|---|---|---|
| Price | $3.39 | $6.84 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | $4.83 | ★ $14.90 |
| AVG Volume (30 Days) | 604.7K | ★ 1.0M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $216,105,000.00 |
| Revenue This Year | $6.32 | $21.35 |
| Revenue Next Year | $4.98 | $37.40 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 8.72 |
| 52 Week Low | $1.60 | $3.81 |
| 52 Week High | $4.48 | $9.91 |
| Indicator | HLLY | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 57.46 | 42.83 |
| Support Level | $2.72 | $6.57 |
| Resistance Level | $3.47 | $8.29 |
| Average True Range (ATR) | 0.12 | 0.32 |
| MACD | 0.06 | -0.02 |
| Stochastic Oscillator | 91.74 | 25.40 |
Holley Inc designs, manufactures, and distributes high-performance automotive aftermarket products to car and truck enthusiasts in the United States, Canada and Europe. It manufactures a diversified line of performance automotive products, including carburetors, fuel pumps, fuel injection systems, nitrous oxide injection systems, superchargers, exhaust headers, mufflers, distributors, ignition components, engine tuners and automotive performance plumbing products. It also manufactures exhaust products as well as shifters, converters, transmission kits, transmissions, tuners and automotive software. The company markets its products under brands such as Holley, Holley EFI, MSD, Simpson, Flowmaster, EDGE, Cataclean, and Accel, among others. It operates in single segment.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.